Cidara Therapeutics to Present New Data for Rezafungin at TIMM Congress

NEXT STORY
Medolife Rx Files Bi-Annual Report With Ministry of Environment in the Dominican Republic, Details Reservation Expansion and Exceeds Regulatory Expectations
PREV STORY
Vaxil Announces Progress on Research and Development Activities
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

iTeos Therapeutics Completes $75 Million Series B Financing

iTeos Therapeutics Completes $75 Million Series B Financing   Oversubscribed financing round led by ...

author_avatar
NASDAQ Market News

Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results

Company Pursuing U.S. Vitaros Partnership and Strategic AlternativesSAN DIEGO, May 03, 2018 (GLOBE NEWSWIRE) ...

author_avatar
NASDAQ Market News

Novartis announces EU approval of Gilenya® for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in Europe

Approval based on landmark PARADIGMS study showing Gilenya (fingolimod) significantly reduced relapse rates by ...

author_avatar
NASDAQ Market News